-
3 weeks ago | 
jacc.org | Andrew Chang |Joel D. Kaufman |Annabel Tan |Sanjiv Shah
References1. "Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019". Lancet . 2020;396:1223-1249. 2. "Global association of air pollution and heart failure: a systematic review and meta-analysis". Lancet . 2013;382:1039-1048. 3. "The Cardiovascular Health Study: design and rationale". Ann Epidemiol . 1991;1:263-276. 4.
-
Jan 6, 2025 | 
digitalcommons.library.tmc.edu | Ambarish Pandey |Sanjiv Shah |Javed Butler |Dean Kellogg
KeywordsAging, Animals, Exercise Tolerance, Heart Failure, Diastolic, HumansAbstractExercise intolerance (EI) is the primary manifestation of chronic heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure among older individuals.
-
Nov 27, 2024 | 
radcliffecardiology.com | Sanjiv Shah |Ashley Park |Andrew Coats |Nazli Okumus
Video Published: Views: 22 Likes: 0 Average (ratings) AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).
-
Oct 28, 2024 | 
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03264-4, published online 1 September 2024. In the version of the article initially published, the first three columns of the “New-onset atrial fibrillation” row of Fig. 1 originally read “286 (3.0)”, “1.3”, “345 (3.6)” and have now been amended to “286 (3.9)”, “1.4”, “345 (4.7)” in the HTML and PDF versions of the article.
-
Oct 22, 2024 | 
jacc.org | Scott Solomon |John W. Ostrominski |Xiaowen Wang |Sanjiv Shah
Introduction Abnormalities of cardiac structure and function are common in heart failure (HF) and remain powerful predictors of HF onset and progression.1-4 Increasing evidence indicates that obesity is a major driver of both adverse cardiac remodeling and HF, particularly heart failure with preserved ejection fraction (HFpEF).5-10 Indeed, obesity-related HFpEF is now recognized as a widely prevalent and high-risk phenotype within the broader HFpEF spectrum,11,12 characterized by...
-
Oct 1, 2024 | 
radcliffecardiology.com | Sanjiv Shah |Erin D. Michos |Alison Bailey |Tina Ticinovic Kurir
Video Published: Views: 2 Likes: 0 Average (ratings) HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892). EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.
-
Sep 30, 2024 | 
jamanetwork.com | Sanjiv Shah |Bristol Myers Squibb |New jersey |Ravi B. Patel
Key PointsQuestion
What effect does the cardiac myosin inhibitor mavacamten have on cardiac biomarkers in patients with heart failure with preserved ejection fraction (HFpEF) and left ventricular ejection fraction (LVEF) of 60% or greater, and is mavacamten safe in these patients?
-
Sep 12, 2024 | 
onlinelibrary.wiley.com | Tess Peterson |Joao Lima |Sanjiv Shah |David A. Bluemke
Introduction Heart failure (HF) diagnosis is largely limited to symptomatic stages,1 before which preclinical alterations in cardiac structure often occur.2-4 These diagnostic limitations are highly problematic due to the high prevalence of asymptomatic subclinical disease5, 6 and high mortality after incident HF diagnosis.7 Heterogeneity in HF pathophysiology contributes to the challenge of early diagnosis and treatment.
-
Sep 1, 2024 | 
nature.com | Pardeep S. Jhund |Meike Brinker |Peter Kolkhof |Michele Senni |Sanjiv Shah |Adriaan A. Voors | +3 more
AbstractCardiovascular-kidney-metabolic syndrome is an emerging entity that connects cardiovascular diseases, chronic kidney disease, and diabetes. The non-steroidal mineralocorticoid receptor antagonist, finerenone, has been studied in three prospective randomized clinical trials of patients with cardio-kidney-metabolic syndrome: FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF.
-
Aug 13, 2024 | 
nature.com | Carine Hamo |Nick Hartshorne-Evans |Sanjiv Shah
AbstractHeart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and has a prevalence that is expected to rise with the growing ageing population. HFpEF is associated with significant morbidity and mortality. Specific HFpEF risk factors include age, diabetes, hypertension, obesity and atrial fibrillation.
